Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C4 | P17516 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | STK39 | Q9UEW8 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | PARG | Q86W56 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1114777 | 0.80 | KCNMA1 (0.54) | MAPK1ALDH1A1 | |
| SCHEMBL1115005 | 0.77 | KDM4E (0.50) | MAPK1ALDH1A1POLBRXFP1 | |
| SCHEMBL1114971 | 0.74 | TTR (0.40) | TBXAS1MAPK1PTGS2MAPK14POLB | |
| SCHEMBL1115000 | 0.74 | HSPD1 (0.50) | AKR1C4AKR1C3AKR1C2AKR1C1PTGS1 | |
| SCHEMBL13320226 | 0.73 | AKR1C4 (0.56) | AKR1C4AKR1C3AKR1C2AKR1C1PTGS1 | |
| SCHEMBL1114875 | 0.73 | GAA (0.45) | MAPK1ALDH1A1 | |
| SCHEMBL3713890 | 0.73 | AKR1C4 (0.60) | AKR1C4AKR1C3AKR1C2AKR1C1PTGS1 | |
| SCHEMBL19321444 | 0.73 | AKR1C4 (0.60) | AKR1C4AKR1C3AKR1C2AKR1C1PTGS1 | |
| SCHEMBL11237433 | 0.72 | AKR1C4 (0.64) | AKR1C4AKR1C3AKR1C2AKR1C1PTGS1 | |
| SCHEMBL2454782 | 0.72 | AKR1C4 (0.55) | AKR1C4AKR1C3AKR1C2AKR1C1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2279732-A2 | Compounds and compositions for delivering active agents | Emisphere Technologies, Inc. (US) | 2011-02-02 | — | — | EP | claimed |
| US-8273794-B2 | 7-[isopropyl(phenyl)amino]-7-oxoheptanoic acid, 3-(2-Hydroxy-benzoylamino)-butyric acid, 4-Oxo-4-phenyl-butyric acid, 10-(2-Hydroxy-phenyl)-10-oxo-decanoic acid, 4-(4-Methoxy-phenyl)-4-oxo-butyric acid: promoting the absorption of the active agent | EMISPHERE TECHNOLOGIES, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273794-B2 | 7-[isopropyl(phenyl)amino]-7-oxoheptanoic acid, 3-(2-Hydroxy-benzoylamino)-butyric acid, 4-Oxo-4-phenyl-butyric acid, 10-(2-Hydroxy-phenyl)-10-oxo-decanoic acid, 4-(4-Methoxy-phenyl)-4-oxo-butyric acid: promoting the absorption of the active agent | EMISPHERE TECHNOLOGIES, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2279732-A2 | Compounds and compositions for delivering active agents | Emisphere Technologies, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| EP-2279732-A2 | Compounds and compositions for delivering active agents | Emisphere Technologies, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20080255250-A1 | Compounds and Compositions for Delivering Active Agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255250-A1 | Compounds and Compositions for Delivering Active Agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| EP-1756039-A4 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1756039-A2 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | Emisphere Technologies, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005112633-A2 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255250-A1 | Compounds and Compositions for Delivering Active Agents | SERPINB1, ELANE, MMP8 | AKR1C4 2425/4885AKR1C3 2266/4885AKR1C2 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.